Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3119)	12/27/2010 12:49:15 PM
From: Jibacoa	Respond to of 3722

SPPI has continued its recent UT. The stock is up another 6% with volume about 3/4 its ADV. bigcharts.marketwatch.com Last week it announced that the target enrollment had been reached for the PII of belinostat in Carcinoma of Unknown Primary. <g> That PII, is being conducted and fully funded by SPPI's partner, Topotarget A/S. Belinostat is an HDAC inhibitor with the potential safety advantage that allows for full-dose combination with other chemotherapeutic regimens, including carboplatin and paclitaxel. Topotarget expects to have the results of that PII available in the 3rdQ. But final evaluation of overall survival is not expected until the first quarter of 2012. The ACTAY is $10.38 SPPI has a relatively small LTD, but has been burning its cash at a good clip.<g> With some good news the stock has plenty of room to run.<g> bigcharts.marketwatch.com Bernard